普拉克索缓释片临床应用.pptVIP

Of the 87 patients successfully switched to pramipexole sustained release (SR) , 72 (82.8%) did not require dose adjustment. In the ER group overall (n = 103), mean SR dosage was only marginally increased by 0.12 mg/d (from 2.63 to 2.75), for a ratio of 1:1.05. In the immediate-release (IR) group overall (n = 52), the increase was 0.09 mg/d (from 2.74 to 2.83), for a ratio of 1:1.03. Based on these data, a 1:1 mg overnight switch from pramipexole IR to SR can be recommended. However, a small proportion of patients may require some dose modification following switching1. Reference Rascol O, Barone P, Debieuvre C, et al. Easy switching from immediate- to extended-release pramipexole in early Parkinson’s disease at the same daily dosage. Poster presented at the Movement Disorder Society 13th International Congress, Paris, France, June 7-11, 2009, Th-255. Mean Unified Parkinson’s Disease Rating Scale (UPDRS) Parts II+III scores decreased in both groups during the trial; adjusted mean change at 9 weeks was greater for sustained release (SR) versus immediate release (IR) but the difference was not statistically significant (–1.6 versus –0.5; P = 0.21, ANCOVA). Although the lower limit of the 95% CI for difference in successful-switch rate between the SR and the IR group exceeded the pre-specified margin (-9.76 vs. -3.0 planned), so that the non-inferiority of SR to IR was not formally demonstrated, the once-a-day formulation was not different from IR on UPDRS II+III scores and Clinical Global Impression—Improvement (CGI-I) and Patient Global Impression—Improvement (PGI-I) responder rates, further suggesting that SR and IR were comparably effective1. Reference Rascol O, Barone P, Debieuvre C, et al. Easy switching from immediate- to extended-release pramipexole in early Parkinson’s disease at the same daily dosage. Poster presented at the Movement Disorder Society 13th International Congress, Paris, France, June 7-11, 2009, Th-255. This trial demonstrated that more than